Business UpdateJul 9, 2026, 04:03 PM
Denali CEO to Deliver AAIC Plenary on Neurodegeneration
AI Summary
Denali Therapeutics announced that co-founder and CEO Ryan Watts will deliver the opening plenary address at the 2026 Alzheimer’s Association International Conference (AAIC) in London. The presentation will focus on accelerating the discovery and development of medicines for neurodegeneration, including insights into disease biology, biomarkers, and blood-brain barrier therapeutics. The company highlighted its clinically validated TransportVehicle™ platform, which was leveraged for AVLAYAH™'s FDA accelerated approval in March 2026, and provided updates on investigational Alzheimer's therapies DNL628 and DNL921, with clinical data for both expected in 2027.
Key Highlights
- CEO Ryan Watts to deliver opening plenary address at 2026 AAIC on July 12, 2026.
- Presentation will highlight scientific advances and future opportunities in neurodegenerative disease.
- Denali's TransportVehicle™ platform enables therapeutics to cross the blood-brain barrier.
- AVLAYAH™ received FDA accelerated approval in March 2026 for Hunter syndrome.
- DNL628 (OTV:MAPT) Phase 1b clinical study initiated in H1 2026; data expected 2027.
- DNL921 (ATV:Abeta) CTA submitted in H1 2026; Phase 1/1b trial initiation pending regulatory approval.
- Clinical safety and biomarker proof-of-concept data for DNL921 expected in 2027.
Price Impact
More from DNLI